Paola Cicconi

University of Oxford - The Jenner Institute

Mansfield Road

Oxford, OX1 4AU

United Kingdom

University of Oxford - Oxford Vaccine Group

Oxford

United Kingdom

SCHOLARLY PAPERS

4

DOWNLOADS
Rank 549

SSRN RANKINGS

Top 549

in Total Papers Downloads

72,450

TOTAL CITATIONS

48

Scholarly Papers (4)

1.

Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

Number of pages: 37 Posted: 01 Feb 2021
University of Oxford - Oxford Vaccine Group, University of Siena - Institute of Global Health, University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit, Federal University of São Paulo (UNIFESP), University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Oxford Vaccine Group, University of the Witwatersrand, Stellenbosch University - Family Centre for Research with Ubuntu, Soweto Clinical Trials Centre, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of the Witwatersrand - South African Medical Research Council Vaccines and Infectious Diseases Analytical Research Unit, University of Sheffield - Department of Infection, Immunity and Cardiovascular Disease, University of Cape Town (UCT) - Centre for Lung Infection and Immunity, University of Oxford - Jenner Institute, Newcastle upon Tyne Hospitals NHS Foundation Trust - Department of Infection and Tropical Medicine, University of Oxford - Oxford Vaccine Group, GSK plc, University of Oxford - The Jenner Institute, Wits Reproductive Health & HIV Institute (WRHI), University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Oxford - Oxford Vaccine Group, University of Liverpool - School of Tropical Medicine, University of Bristol - Bristol Vaccine Centre, St George’s University London - St George’s Vaccine Institute, University College London - Department of Infection, University of Oxford - Clinical BioManufacturing Facility, University Hospitals Birmingham NHS Foundation Trust, University of Oxford - Oxford Vaccine Group, University of the Witwatersrand - South African Medical Research Council, Liverpool School of Tropical Medicine - Department of Clinical Sciences, AstraZeneca Pharmaceuticals, University of the Witwatersrand - South African Medical Research Council, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of the Witwatersrand - South African Medical Research Council, University of the Witwatersrand - South African Medical Research Council, University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, University College London, Hull University Teaching Hospitals NHS Trust, University of Oxford - Centre for Vaccinology and Tropical Medicine, AstraZeneca Pharmaceuticals, Braziland Hospital São Rafael - Escola Bahiana de Medicina e Saúde Pública, Universidade Federal do Rio Grande do Norte (UFRN), University of Oxford - The Jenner Institute, London Northwest University Healthcare, University of Oxford - Oxford Vaccine Group, University of the Witwatersrand - Perinatal HIV Research Unit, Setshaba Research Centre, University of Oxford - Oxford Vaccine Group, Hospital Quinta D'OR, University of Oxford - Oxford Vaccine Group, Imperial College London - Department of Infectious Disease, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, Hospital Universitário de Santa Maria, University of Glasgow - College of Medical, Veterinary & Life Sciences, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Western General Hospital - Clinical Infection Research Group, MRC-University of Glasgow Centre for Virus Research, University of Cambridge - Department of Medicine, Royal Papworth HospitalUniversity of Cambridge - Heart and Lung Research Institute, Nottingham University Hospitals NHS Trust, AstraZeneca Biopharmaceuticals, AstraZeneca Pharmaceuticals, AstraZeneca Pharmaceuticals, Anuerin Bevan University Health Board, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Chinese Academy of Medical Science Oxford Institute (COI), University of Oxford - Oxford Vaccine Group and Independent
Downloads 52,477 (55)
Citation 3

Abstract:

Loading...

2.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)

Number of pages: 40 Posted: 04 Feb 2021
University of Oxford - Oxford Vaccine Group, University of Oxford - Big Data Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Cambridge, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Cambridge - Department of Medicine, University of Oxford - Big Data Institute, University of Oxford - The Jenner Institute, Public Health England - National Infection Service, University of Oxford - Centre for Vaccinology and Tropical Medicine, Liverpool School of Tropical Medicine - Department of Clinical Sciences, UK Biocentre, University of Sheffield - Department of Infection, Immunity and Cardiovascular Disease, University of Oxford - Oxford Vaccine Group, University of Oxford - Jenner Institute, Newcastle upon Tyne Hospitals NHS Foundation Trust - Department of Infection and Tropical Medicine, GSK plc, University of Oxford - The Jenner Institute, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Liverpool - School of Tropical Medicine, University of Oxford - Oxford Vaccine Group, University of Bristol - Bristol Vaccine Centre, University of Oxford - The Jenner Institute, University of Oxford - Jenner Institute, St George’s University London - St George’s Vaccine Institute, University College London - Department of Infection, University of Oxford - Clinical BioManufacturing Facility, University Hospitals Birmingham NHS Foundation Trust, University of Oxford - Oxford Vaccine Group, Public Health England - National Infection Service, University of London - Institute of Infection and Immunity, Queen Elizabeth University Hospital, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, University College London, Hull University Teaching Hospitals NHS Trust, Genomics England, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, London Northwest University Healthcare, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, Imperial College London - Department of Infectious Disease, University of Oxford - Oxford Vaccine Group, University of Glasgow - College of Medical, Veterinary & Life Sciences, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, Western General Hospital - Clinical Infection Research Group, MRC-University of Glasgow Centre for Virus Research, Royal Papworth HospitalUniversity of Cambridge - Heart and Lung Research Institute, Nottingham University Hospitals NHS Trust, AstraZeneca Biopharmaceuticals, AstraZeneca Pharmaceuticals, Anuerin Bevan University Health Board, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Chinese Academy of Medical Science Oxford Institute (COI), University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, Independent and Independent
Downloads 11,037 (1,051)
Citation 26

Abstract:

Loading...

3.

Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)

Number of pages: 35 Posted: 28 Jun 2021
University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Oxford Vaccine Group, University of Oxford - The Jenner Institute, University of Oxford - Oxford Vaccine Group, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - Wellcome Centre for Human Genetics, University of Oxford - Oxford Vaccine Group, GSK plc, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - Chinese Academy of Medical Science Oxford Institute (COI), University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - Chinese Academy of Medical Science Oxford Institute (COI), University of Oxford - Chinese Academy of Medical Science Oxford Institute (COI), University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - The Jenner Institute and Independent
Downloads 8,779 (1,527)
Citation 19

Abstract:

Loading...

4.

Safety and Broad Immunogenicity of HIVconsvX Conserved Mosaic Candidate T-Cell Vaccines Vectored by ChAdOx1 and MVA in HIV-CORE 006: A Double-Blind, Randomized, Placebo-Controlled Phase 1 Trial in Healthy Adults Living Without HIV-1 in Eastern and Southern Africa

Number of pages: 24 Posted: 26 Mar 2024
Center for Family Health Research Zambia (CFHRZ), Government of Uganda - Uganda Virus Research Institute (UVRI), University of Nairobi, Kenya Medical Research Institute (KEMRI) - Kemri-Wellcome Trust Research Programme, IAVI, University of Oxford, IAVI, University of Oxford, MRC/UVRI & LSHTM Uganda Research Unit, University of Oxford, University of Nairobi, Center for Family Health Research Zambia (CFHRZ), IAVI, IAVI, Kenya Medical Research Institute (KEMRI) - Kemri-Wellcome Trust Research Programme, University of Oxford, IAVI, Imperial College London - IAVI Human Immunology Laboratory, Kenya Medical Research Institute (KEMRI) - Kemri-Wellcome Trust Research Programme, IAVI, University of Oxford, MRC/UVRI & LSHTM Uganda Research Unit, affiliation not provided to SSRN, Imperial College London - IAVI Human Immunology Laboratory, Center for Family Health Research Zambia (CFHRZ), Center for Family Health Research Zambia (CFHRZ), affiliation not provided to SSRN, Center for Family Health Research Zambia (CFHRZ), MRC/UVRI & LSHTM Uganda Research Unit, Medical Research Council/Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM), Kenya Medical Research Institute (KEMRI) - Kemri-Wellcome Trust Research Programme, International AIDS Vaccine Initiative, Imperial College London - IAVI Human Immunology Laboratory, Center for Family Health Research Zambia (CFHRZ), University of Nairobi, University of Nairobi, IAVI, Center for Family Health Research Zambia (CFHRZ), Center for Family Health Research Zambia (CFHRZ), London School of Hygiene & Tropical Medicine - Uganda Research Unit, University of Nairobi, MRC/UVRI & LSHTM Uganda Research Unit, Oxus Technologies Limited, University of Nairobi, Center for Family Health Research Zambia (CFHRZ), University of Nairobi, Center for Family Health Research Zambia (CFHRZ), Center for Family Health Research Zambia (CFHRZ), University of Nairobi, MRC/UVRI & LSHTM Uganda Research Unit, MRC/UVRI & LSHTM Uganda Research Unit, Kenya Medical Research Institute (KEMRI) - Kemri-Wellcome Trust Research Programme, IAVI, University of Nairobi, University of Nairobi, UVRI-IAVI HIV Vaccine Program, University of Nairobi, Kenya Medical Research Institute (KEMRI) - Kemri-Wellcome Trust Research Programme, IAVI, Kenya Medical Research Institute (KEMRI) - Kemri-Wellcome Trust Research Programme, University of California, San Francisco (UCSF) - Department of Medicine, IAVI, University of Nairobi, London School of Hygiene & Tropical Medicine - Uganda Research Unit, University of Oxford, Imperial College London - IAVI Human Immunology Laboratory, University of Oxford - The Jenner Institute, International AIDS Vaccine Initiative, Imperial College London - Department of Infectious Disease, University of Nairobi, London School of Hygiene & Tropical Medicine - Uganda Research Unit, Center for Family Health Research Zambia (CFHRZ), IAVI, Kenya Medical Research Institute (KEMRI) - Kemri-Wellcome Trust Research Programme and University of Oxford - The Jenner Institute
Downloads 157 (407,810)

Abstract:

Loading...

T cells, T-cell vaccine, HIV vaccine: conserved regions, phase I trial, HIVconsvX, ChAdOx1, MVA, vaccine safety, vaccine immunogenicity, clinical trial, virus inhibition assay, HIV-1